Imaging features of myeloproliferative neoplasms

Murphy, Ian; Mitchell, Erica L.; Rásó‐Barnett, Lívia; Godfrey, Anna L.; Godfrey, Edmund

doi:10.1016/j.crad.2017.05.014

Cited by 14 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic myelomonocytic leukemia (CMML) is another rare BCR-ABL-negative myeloid neoplasms with different molecular mechanisms. Beside hematological complications (cytopenia, thrombosis, splenomegaly, progression toward acute myeloid leukemia), BCR-ABL-negative MPN can also lead to systemic disorders characterized by poor prognosis 5,6 .…”

Section: Introductionmentioning

confidence: 99%

Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL–Negative Myeloproliferative Neoplasms

Béllière

Colombat

Kounde

et al. 2021

Kidney International Reports

View full text Add to dashboard Cite

Introduction The identification of specific molecular signatures and the development of new targeted drugs have changed the paradigm of onco-nephrology, now allowing a multiscale approach of kidney involvement related to hematologic malignancies relying on combined hematologic and molecular assessments. In this study, we aimed to refine the spectrum of kidney disorders associated with chronic myelomonocytic leukemia (CMML) or BCR-ABL–negative myeloproliferative neoplasms (MPNs), 2 very rare conditions scarcely described. Methods Case series. Patients with myeloid neoplasms who were referred to Toulouse University Hospital Nephrology Unit and were diagnosed with acute kidney injury (AKI), chronic kidney disease (CKD), or urine abnormalities were retrospectively included. Results Eighteen patients (males n =13, CMML n =8, essential thrombocytosis [ET] n =7, polycythemia vera [PV] n =1, and myelofibrosis n =2) developed kidney disease 7.7±2 years after the diagnosis of the malignancy. Twelve patients had AKI at presentation. Eight patients had glomerular presentation (high-range proteinuria 33%, microscopic hematuria 56%). Kidney biopsy ( n =14) showed various patterns, including pauci-immune glomerulosclerosis ( n =5), extramedullary hematopoiesis ( n =6), or tubular atrophy and interstitial fibrosis with polymorphic inflammation ( n =8). Immunostaining of CD61 confirmed the infiltration of megakaryocytes within glomeruli or interstitium in 5 of 8 patients. Other pictures of glomerulopathy were identified in 3 patients (IgA nephropathy n =2, AA amyloidosis n =1). Massive kidney infiltration by CMML was identified in 1 patient. After a mean follow-up of 24±6 months, malignancy was considered as stable in 11 patients (61%), but 22% of patients had progressed to end-stage renal failure. The remaining had persistently reduced kidney function. No correlation between the malignancy and the renal presentation and outcomes could be identified. Conclusions Kidney complications of CMML/MPN are heterogenous, and kidney biopsy may help to identify new molecular targets to prevent the development of kidney fibrosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL–Negative Myeloproliferative Neoplasms

Béllière

Colombat

Kounde

et al. 2021

Kidney International Reports

View full text Add to dashboard Cite

show abstract

“…Up to 10% of patients experience a thromboembolic event, most commonly venous thromboembolism [6]. Splenomegaly is an inevitable outcome and may lead to splenic infarction, haemorrhage, splanchnic vein thrombosis, portal hypertension, or mass effect symptoms [4, 7–9]. There is also a small risk of progression to acute myeloid leukaemia [10].…”

Section: Epidemiology Clinical Features and Presentationsmentioning

confidence: 99%

Primary myelofibrosis: spectrum of imaging features and disease-related complications

et al. 2019

View full text Add to dashboard Cite

Primary myelofibrosis is a chronic clonal stem cell disorder that results in a build-up of marrow fibrosis and dysfunction, hypermetabolic states, and myeloid metaplasia. The clinical and radiological consequences can be quite diverse and range from the manifestations of osteosclerosis and extramedullary haematopoiesis to thrombohaemorrhagic complications from haemostatic dysfunction. In addition, there is the challenge of identifying less well-recognised sites of extramedullary haematopoiesis and their site-specific complications. The intent of this article is to illustrate the spectrum of primary myelofibrosis as declared though multimodality imaging, with examples of both common and rarer disease manifestations.

show abstract

“…Furthermore, imaging will continue to be used for the assessment of complications of tumour diseases and their therapies, e.g. venous thrombosis or abscess formation [14].…”

Section: Competitiveness and Complementarity Of Liquid Biomarkersmentioning

confidence: 99%

The changing face of cancer diagnosis: From computational image analysis to systems biology

Kießling

2018

Eur Radiol

View full text Add to dashboard Cite

show abstract

Imaging features of myeloproliferative neoplasms

Cited by 14 publications

References 41 publications

Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL–Negative Myeloproliferative Neoplasms

Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL–Negative Myeloproliferative Neoplasms

Primary myelofibrosis: spectrum of imaging features and disease-related complications

The changing face of cancer diagnosis: From computational image analysis to systems biology

Contact Info

Product

Resources

About